Stage 4 Kidney Cancer, Type 1 Diabetes, and a Promise That Was Kept
Clay is from Frisco, Texas. He is a Stage 4 clear cell renal cell carcinoma patient — and his case is one of the most complex the Immunotherapy Institute has managed in recent memory. Type 1 diabetic. Heart stent. High blood pressure. Cancer that has spread beyond the kidney. A body that demands daily adjustments, careful monitoring, and a clinical team willing to treat him as the specific, individual human being he is — not as a data point in a standardized protocol.
Before agreeing to come to Tijuana, Clay asked Dr. Perez a direct question: would he experience the side effects he associated with conventional cancer treatment — the nausea, the hair loss, the exhaustion, the feeling of being destroyed by the medicine meant to save him? Dr. Perez made a promise: no. Those side effects would not be part of Clay's treatment.
That promise has been kept. And his cancer is shrinking.
"I'm not just one of 250 people getting stuck in a study," Clay said. "They know me. They've adjusted my protocol every single day based on how I'm doing." In those words is the entire philosophy of the Immunotherapy Institute — and the entire reason Clay is here rather than enrolled in a clinical trial back in Texas.
Meet Clay: A Complex Case That Demanded More Than a Standard Protocol
Clay's medical history is not simple. As a Type 1 diabetic with cardiovascular complications — including a heart stent and high blood pressure — his body requires constant, careful management even without the added challenge of Stage 4 cancer. Any cancer treatment he received would need to account not only for the tumor burden but for the metabolic and cardiovascular demands of his existing conditions.
Conventional oncology's response to this kind of complexity is well-intentioned but structurally limited. Standard drug protocols are calibrated for populations, not individuals. The dose is the dose — adjusted for weight and kidney function, perhaps, but not for the specific daily reality of a Type 1 diabetic whose insulin requirements shift with every infusion. Not for the cardiovascular considerations of a man with a heart stent who is also receiving immune-stimulating therapies.
Clay needed a team that would make adjustments daily. Not weekly, not after bloodwork came back from a lab three states away — daily. He found that team in Tijuana.
Stage 4 Renal Cell Carcinoma With Multiple Comorbidities — and the Limits of Standardized Care
Stage 4 clear cell renal cell carcinoma carries a challenging prognosis within conventional oncology. The standard of care involves targeted therapies — tyrosine kinase inhibitors, immune checkpoint inhibitors — that can be effective but produce significant side effects. For a patient like Clay, whose cardiovascular system and metabolic function are already under additional stress, those side effects are not just uncomfortable. They can be dangerous.
The clinical trial model that U.S. oncology often points toward for patients like Clay — Stage 4, complex comorbidities, not an ideal candidate for standard protocols — is, from a patient's perspective, deeply impersonal. Eligibility requirements, dosing standardization, fixed follow-up schedules. "One of 250 people getting stuck in a study" is not just a colloquial complaint. It is a description of a care model where the protocol takes precedence over the person.
Clay was not willing to accept that model. His niece, Dr. Katie Jarvis, had researched the Immunotherapy Institute and understood what it offered. Together, they made the decision to come to Tijuana — where the protocol would be built around Clay, adjusted daily, and held to a standard of personal accountability that no clinical trial could replicate.
A Promise About Side Effects — and a Protocol Built Around One Person
The conversation that sealed Clay's decision to come to the Immunotherapy Institute was the one where Dr. Perez addressed his most immediate concern directly. Clay had seen what conventional cancer treatment looked like. He had seen what it did to people. He needed to know whether the treatment in Tijuana would do the same thing to him.
Dr. Perez's answer was unequivocal: no. The institute's immunotherapy protocols do not produce the systemic destruction associated with high-dose chemotherapy. The treatment is designed to strengthen and deploy the immune system — not to poison the body indiscriminately in hopes of taking the cancer with it. There would be no nausea, no hair loss, no bone marrow suppression, no collapse of the immune system that was supposed to be fighting the disease.
That promise was meaningful enough to bring Clay to Tijuana. What he found when he arrived went beyond the promise. The team conducted a hair sample analysis to establish a detailed picture of his nutritional status — identifying deficiencies and establishing a support plan calibrated specifically to his metabolic needs as a Type 1 diabetic. And from the first day of treatment, the protocol was adjusted. Not according to a fixed schedule, but in response to how Clay was actually doing, hour by hour and day by day.
Daily Adjustments, Hair Sample Analysis, and a Cancer That Is Shrinking
Clay's treatment at the Immunotherapy Institute has been defined by two things: its personalization and its responsiveness. Every day, the clinical team has assessed his condition and adjusted the protocol accordingly — managing the intersection of his Stage 4 kidney cancer, his Type 1 diabetes, his cardiovascular status, and his overall energy and wellbeing in real time. This is not a hypothetical benefit of the institute's model. For Clay, it has been a daily reality.
The nutritional assessment conducted through hair sample analysis is characteristic of the clinic's whole-person approach. Rather than applying a standard cancer nutrition protocol, the team identified Clay's specific micronutrient status and built a support plan around what his body actually needed — particularly important for a Type 1 diabetic whose insulin sensitivity and metabolic function interact with cancer treatment in complex ways.
The immunotherapy protocols — which can include dendritic cell therapy, NK cell therapy, and targeted immune stimulation — are designed to work with Clay's intact immune function, strengthening it and directing it against the cancer rather than suppressing it as a side effect of treatment. No nausea. No hair loss. No systemic collapse.
His cancer is visibly shrinking. His niece, Dr. Katie Jarvis — a physician who has been present throughout — describes the treatment as a military strategy, comprehensive and multi-front, and calls herself thrilled by what she has witnessed. For Clay, the experience has been simpler to articulate: he is being treated as a person, not a protocol. And it is working.
The Promise Kept — and a Patient Who Knows He's Not Just a Number
Clay came to Tijuana with Stage 4 kidney cancer, a body full of medical complexity, and one overriding question: would the treatment destroy him in the process of trying to save him? The answer, proven daily across his time at the Immunotherapy Institute, is no.
His cancer is shrinking. He has not experienced the side effects that he associated with cancer treatment — the ones that had made him hesitant to pursue treatment at all. He is being seen, adjusted for, and cared for as the specific human being he is, with the specific complications his history presents, by a team that has made daily modifications to his protocol in response to his actual condition.
"I'm not just one of 250 people getting stuck in a study." That sentence carries everything. It carries the frustration of a patient who knows he would be poorly served by a standardized protocol. It carries the relief of a patient who found something different. And it carries the dignity of a man who, in the middle of one of the most frightening experiences a person can have, is being treated as an individual — with individual DNA, an individual history, and an individual need — by a team that has committed to meeting him exactly where he is.
“I'm not just one of 250 people getting stuck in a study. They know me. They've adjusted my protocol every day. Dr. Perez promised no typical side effects — and he kept that promise.”
Key Takeaways from Clay's Story
Clay's case is one of the most medically complex the Immunotherapy Institute has managed — and his experience reveals exactly what personalized, integrative cancer care looks like in practice:
✓ Stage 4 kidney cancer patients with serious comorbidities — including Type 1 diabetes, cardiovascular conditions, and high blood pressure — can receive safe, effective, and fully individualized treatment at the Immunotherapy Institute, with daily protocol adjustments made in response to their specific daily condition.
✓ The immunotherapy protocols at the Immunotherapy Institute do not produce the side effects associated with conventional chemotherapy — no nausea, hair loss, or immune suppression — making them accessible to patients who cannot tolerate or have declined conventional treatment.
✓ Hair sample analysis for nutritional assessment is one of the tools the Immunotherapy Institute uses to personalize its protocols — identifying specific deficiencies and establishing a support plan calibrated to the individual patient, which is particularly important for patients with metabolic conditions.
✓ Daily physician access and daily protocol adjustment are structural features of care at the Immunotherapy Institute — not exceptional service, but standard practice — and for medically complex patients like Clay, that daily responsiveness is a clinical necessity.
✓ Clay's case demonstrates that Stage 4 renal cell carcinoma, even with significant comorbidities, can respond to integrative immunotherapy — with visible tumor reduction occurring in a patient whose conventional oncology options were limited by the complexity of his overall medical profile.
Frequently Asked Questions
Questions we hear most from Stage 4 kidney cancer patients with complex medical histories considering the Immunotherapy Institute:
Can the Immunotherapy Institute treat kidney cancer patients who also have Type 1 diabetes or other serious conditions?
Yes — and Clay's case is the clearest evidence. He arrived with Stage 4 renal cell carcinoma, Type 1 diabetes, a heart stent, and high blood pressure, and the Immunotherapy Institute's team made daily adjustments to his protocol in response to how his body was responding. The clinic's approach accounts for the full complexity of the patient's medical picture, rather than treating the cancer in isolation. Patients with serious comorbidities should share their complete medical history during the pre-arrival consultation so the team can build an appropriate and safe protocol.
Does treatment at the Immunotherapy Institute cause the same side effects as conventional chemotherapy?
For patients receiving the institute's immunotherapy protocols, the side effect profile is fundamentally different from conventional chemotherapy. Immunotherapy works by strengthening and directing the immune system against the cancer — not by delivering cytotoxic drugs that damage healthy tissue indiscriminately. Clay's treatment was specifically designed to avoid nausea, hair loss, bone marrow suppression, and immune system damage. Dr. Perez made that promise to Clay before he arrived, and it was kept. The specific side effect profile depends on the individual protocol, which is why a detailed pre-arrival consultation is essential.
What is hair sample analysis and why does the Immunotherapy Institute use it?
Hair sample analysis allows the clinic to assess the patient's trace mineral and micronutrient status at a cellular level — identifying deficiencies that blood tests may not capture and that significantly affect immune function, energy, and treatment response. For a Type 1 diabetic like Clay, understanding the specific nutritional needs of his metabolism is essential for building a treatment and nutrition plan that will actually support his healing. This level of nutritional personalization is characteristic of the Immunotherapy Institute's whole-person approach.
How often are treatment protocols adjusted at the Immunotherapy Institute?
For Clay, adjustments were made daily — in response to his blood glucose levels, energy, and how his body was responding to each day's treatment. This daily responsiveness is particularly important for medically complex patients whose condition can shift significantly from one day to the next. The institute's model, which gives patients direct access to their treating physicians throughout the day, makes this level of real-time protocol management possible in a way that fixed clinical trial protocols or scheduled oncology appointments cannot replicate.
Is the Immunotherapy Institute a realistic option for Stage 4 kidney cancer patients from Texas or other U.S. states?
Yes. Clay is from Frisco, Texas, and his niece — a US physician — accompanied him throughout his treatment. The Immunotherapy Institute coordinates all aspects of travel for patients coming from Texas and across the United States, including airport transportation, accommodations, and daily clinic shuttles. The clinic's case management team is in contact with patients and families before, during, and after treatment, making the logistics of cross-border care manageable even for patients whose medical complexity would ordinarily make travel challenging.
Take the Next Step
Clay arrived in Tijuana as a Stage 4 kidney cancer patient with a body full of medical complexity and a simple need: to be treated as a person, not a protocol. Dr. Perez made a promise. The team kept it. His cancer is shrinking.
If you are a Stage 4 kidney cancer patient who has been told the standard protocols aren't a good fit, or whose complexity has made the conventional system feel like it wasn't designed for you — Clay's story is yours. The Immunotherapy Institute was built for exactly this kind of patient: the one who needs more than a standard dose and a follow-up appointment.
Ready to Take the Next Step?
Contact the Immunotherapy Institute today to discuss Stage 4 kidney cancer treatment options — including personalized immunotherapy protocols, daily physician management, and plans that account for your specific medical history, comorbidities, and goals. Consultations available for patients worldwide. Visit immunotherapyinstitute.com to get started.